Hence, the primary goal of the present study was to refine our understanding on the acute vs long term impacts of S1P1 competitive antagonism mediated barrier changes with the help of NIBR-0213, a potent and selective S1P1 competitive antagonist which had previously demonstrated lung leakage effect but also good oral efficacy and tolerability in a mouse model of autoimmune disease [15]. This evidence concerns the gene S1PR1 and autoimmune disease.